- Translating drugs from pre-clinical into a clinical setting
- Dosage of drugs to deliver patient benefit
- Biomarker-based patient selection
- Treatment decisions
- Complexity and variability of disease pathology and biomarkers
- Use of inappropriate samples or data sets for biomarker discovery and validation
- Limited understanding of the disease
- Inappropriate interrogation methodologies and technologies
- Enable drug discovery companies to incorporate relevant biomarkers into their programmes, allowing better decision making and greater success in the clinic
- Establish robust methods to analyse large numbers of analytes in small sample volumes with the highest sensitivity
- Provide integrated data sets across different ‘omics technologies and informatics analysis to provide expert interpretation of these studies
- Develop biomarkers from ’omics experiments into clinically relevant assays
- Develop biomarker strategies to de-risk and accelerate pre-clinical and clinical development
- Access industry standard expertise and multi-plex technology (proteomics, genomics, metabolomics, transcriptomics and lipidomics) to discover biomarkers that indicate drug and disease interaction, disease progression, drug resistance and heterogeneity in patient samples
- Validate existing biomarkers for clinical trial application (especially in therapeutic areas where biomarker analysis is not routine practice) and develop assays to measure these
- Access tools to characterise pre-clinical models, ensuring they are reflective of patients and disease
- Access consented patient samples and data
- Access informatics expertise to interrogate large data sets
